Skip to main content
Bafna Pharmaceuticals Limited logo

Bafna Pharmaceuticals Limited — Investor Relations & Filings

Ticker · BAFNAPH ISIN · INE878I01022 LEI · 984500D03E2C7Y5EE587 BSE.NS Manufacturing
Open in API
Filings indexed 247 across all filing types
Latest filing 2025-03-26 Regulatory Filings
Country IN India
Listing BSE.NS BAFNAPH

About Bafna Pharmaceuticals Limited

http://bafnapharma.com/

Bafna Pharmaceuticals Limited specializes in the development, manufacture, and marketing of a diverse range of pharmaceutical formulations. The company operates manufacturing facilities certified by WHO-GMP standards, ensuring high-quality production of finished dosage forms including tablets, capsules, syrups, and suspensions. Its therapeutic portfolio spans multiple categories such as anti-infectives, analgesics, cardiovascular, gastrointestinal, and vitamins. The organization serves both domestic and international markets, with a significant presence in emerging regions across Africa, Southeast Asia, and the CIS. In addition to its proprietary product line, the company provides comprehensive contract manufacturing and formulation development services, leveraging its technical expertise and regulatory compliance to meet global healthcare requirements.

Recent filings

Filing Released Lang Actions
Trading Window
Regulatory Filings Classification · 95% confidence The document is a formal letter addressed to stock exchanges (BSE and NSE) regarding the closure of the trading window for the quarter and financial year ended March 31, 2025. It references SEBI regulations on insider trading and informs about the trading restrictions for designated persons around the announcement of audited financial results. The document does not contain any financial data, results, or detailed report content. It is an announcement related to trading restrictions ahead of financial results disclosure. The document length is short (2065 characters), and it serves as a notification rather than a report or detailed filing. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2025-03-26 English
Copy of Newspaper Publication
Regulatory Filings
2025-02-11 English
Integrated Filing- Financial
Regulatory Filings
2025-02-06 English
Outcome of Board Meeting
Regulatory Filings
2025-02-06 English
Board Meeting — Board Meeting Intimation
Regulatory Filings
2025-01-28 English
Board Meeting — Financial Results
Board/Management Information Classification · 95% confidence The document is a formal letter from Bafna Pharmaceuticals Limited addressed to stock exchanges, informing about a scheduled Board Meeting to consider and approve the unaudited financial results for the third quarter ended December 31, 2024. It also mentions the closure of the trading window for insiders. The document is short (2201 characters) and serves as an announcement of an upcoming board meeting and financial results approval, not the financial report itself. It does not contain actual financial data or detailed financial statements. Therefore, it is an announcement related to management or board activities, specifically a notice of a board meeting under SEBI regulations. This fits best under the category 'Board/Management Information (MANG)'.
2025-01-28 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.